Human CXCL10/IP-10/CRG-2 Antibody

Catalog #: MAB266R Datasheet

Recombinant Monoclonal Antibody

Catalog #	Availability	Size / Price	Qty
MAB266R-100
MAB266R-SP

Detection of CXCL10 in Human PBMCs by Flow Cytometry.

2 Images

All CXCL10/IP-10/CRG-2 Antibodies

Product Details

FAQs

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL10/IP-10/CRG-2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human CXCL10/IP-10/CRG-2 in direct ELISAs.

Source

Recombinant Monoclonal Mouse IgG₁ Clone # 33036R

Purification

Protein A or G purified from cell culture supernatant

Immunogen

E. coli-derived recombinant human CXCL10/IP-10/CRG-2
Val22-Pro98
Accession # P02778.2

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Intracellular Staining by Flow Cytometry

0.25 µg/10⁶ cells

See below

Human CXCL10/IP-10 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human CXCL10/IP‑10/CRG‑2 Biotinylated Antibody (Catalog # BAF266)

Standard: Recombinant Human CXCL10/IP-10 Protein (Catalog # 266-IP)

Neutralization

Measured by its ability to neutralize CXCL10/IP‑10/CRG‑2-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR3. The Neutralization Dose (ND₅₀) is typically 0.5-2.0 µg/mL in the presence of 0.2 µg/mL Recombinant Human CXCL10/IP‑10/CRG‑2.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Intracellular Staining by Flow Cytometry

Detection of CXCL10 antibody in Human PBMCs antibody by Flow Cytometry.

View Larger

Detection of CXCL10 in Human PBMCs by Flow Cytometry. Human PBMCs were treated with recombinant human INF gamma (Catalog # 285-IF, 10 ng/ml) overnight and stained with Mouse Anti-Human CXCL10 Monoclonal Antibody (Catalog # MAB266R, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) followed by anti-Mouse IgG PE-conjugated secondary antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Membrane-associated Proteins.

Neutralization

View Larger

Chemotaxis Induced by CXCL10/IP-10 and Neutralization by Human CXCL10/IP-10 Antibody. Recombinant Human CXCL10/IP-10 (Catalog # 266-IP) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL10/IP-10 (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL10/IP-10 Monoclonal Antibody (Catalog # MAB266). The ND₅₀ is typically 0.5-2.0 µg/mL.

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL10/IP-10/CRG-2

CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta, TNF-alpha, IL-12, and viruses. Additional cell types that have been shown to express CXCL10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. CXCL10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human CXCL10, CRG-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human CXCL10. Human CXCL10 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted protein. The amino acid sequence of CXCL10 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CXCL10 has been shown to be a chemoattractant for activated T-lymphocytes. CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent antitumor effect. A chemokine receptor specific for CXCL10 and Mig has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

References